Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 17, Issue 2, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-014-0482-5
Keywords
Familial hypercholesterolemia; Diagnosis and screening
Categories
Funding
- Amgen
- Bayer Healthcare
- Pfizer
- Janssen Pharma
- Eli Lilly
Ask authors/readers for more resources
Familial hypercholesterolemia is among the commonest inherited metabolic disorders and is characterized by severely elevated LDL cholesterol levels. Mutations in four genes have been noted in patients with familial hypercholesterolemia (FH):LDL receptor (most common), apolipoprotein B (Apo B), proprotein convertase subtilin/kexin 9 (PCSK9), and low-density lipoprotein receptor adaptor protein (LDLRAP). In most cases, inheritance is autosomal co-dominant with homozygotes having double the LDL cholesterol levels of heterozygotes. Autosomal recessive inheritance is rare. The prevalence of the heterozygous state has been estimated at 1 in 200 to 1 in 500 and of the homozygous state from 1 in 160,000 to 1 in 1,000, 000. Three formal diagnostic criteria have been proposed to diagnose FH in practice-MedPed, Simon Broome, and Dutch Lipid Clinic Network. The role of genetic testing and cascade screening among families is discussed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available